Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Qian Wang; Chunwei Xu; Wenxian Wang; Yongchang Zhang; Ziming Li; Zhengbo Song; Jiandong Wang; Jinpu Yu; Jingjing Liu; Shirong Zhang; Xiuyu Cai; Wen Li; Ping Zhan; Hongbing Liu; Tangfeng Lv; Liyun Miao; Lingfeng Min; Jiancheng Li; Baogang Liu; Jingping Yuan; Zhansheng Jiang; Gen Lin; Xiaohui Chen; Xingxiang Pu; Chuangzhou Rao; Dongqing Lv; Zongyang Yu; Xiaoyan Li; Chuanhao Tang; Chengzhi Zhou; Junping Zhang; Hui Guo; Qian Chu; Rui Meng; Xuewen Liu; Jingxun Wu; Xiao Hu; Jin Zhou; Zhengfei Zhu; Xiaofeng Chen; Weiwei Pan; Fei Pang; Wenpan Zhang; Qijie Jian; Kai Wang; Liping Wang; Youcai Zhu; Guocai Yang; Xinqing Lin; Jing Cai; Huijing Feng; Lin Wang; Yingying Du; Wang Yao; Xuefei Shi; Xiaomin Niu; Dongmei Yuan; Yanwen Yao; Jianhui Huang; Xiaomin Wang; Yinbin Zhang; Pingli Sun; Hong Wang; Mingxiang Ye; Dong Wang; Zhaofeng Wang; Yue Hao; Zhen Wang; Bing Wan; Donglai Lv; Jianwei Yu; Jin Kang; Jiatao Zhang; Chao Zhang; Lixin Wu; Lin Shi; Leiguang Ye; Gaoming Wang; Yina Wang; Feng Gao; Jianfei Huang; Guifang Wang; Jianguo Wei; Long Huang; Bihui Li; Zhang Zhang; Zhongwu Li; Yueping Liu; Yuan Li; Zhefeng Liu; Nong Yang; Lin Wu; Qiming Wang; Wenbin Huang; Zhuan Hong; Guansong Wang; Fengli Qu; Meiyu Fang; Yong Fang; Xixu Zhu; Kaiqi Du; Jiansong Ji; Yi Shen; Jing Chen; Yiping Zhang; Shenglin Ma; Yuanzhi Lu; Yong Song; Anwen Liu; Wenzhao Zhong; Wenfeng Fang

doi:10.1111/1759-7714.15022

Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Qian Wang
, Chunwei Xu
, Wenxian Wang
, Yongchang Zhang
, Ziming Li
, Zhengbo Song
, Jiandong Wang
, Jinpu Yu
, Jingjing Liu
, Shirong Zhang
, Xiuyu Cai
, Wen Li
, Ping Zhan
, Hongbing Liu
, Tangfeng Lv
, Liyun Miao
, Lingfeng Min
, Jiancheng Li
, Baogang Liu
, Jingping Yuan

Zhansheng Jiang, Gen Lin, Xiaohui Chen, Xingxiang Pu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Xuewen Liu, Jingxun Wu, Xiao Hu, Jin Zhou, Zhengfei Zhu, Xiaofeng Chen, Weiwei Pan, Fei Pang, Wenpan Zhang, Qijie Jian, Kai Wang, Liping Wang, Youcai Zhu, Guocai Yang, Xinqing Lin, Jing Cai, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Xiaomin Wang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Yue Hao, Zhen Wang, Bing Wan, Donglai Lv, Jianwei Yu, Jin Kang, Jiatao Zhang, Chao Zhang, Lixin Wu, Lin Shi, Leiguang Ye, Gaoming Wang, Yina Wang, Feng Gao, Jianfei Huang, Guifang Wang, Jianguo Wei, Long Huang, Bihui Li, Zhang Zhang, Zhongwu Li, Yueping Liu, Yuan Li, Zhefeng Liu, Nong Yang, Lin Wu, Qiming Wang, Wenbin Huang, Zhuan Hong, Guansong Wang, Fengli Qu, Meiyu Fang, Yong Fang, Xixu Zhu, Kaiqi Du, Jiansong Ji, Yi Shen, Jing Chen, Yiping Zhang, Shenglin Ma, Yuanzhi Lu, Yong Song, Anwen Liu, Wenzhao Zhong, Wenfeng Fang

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high-risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow-up.

Original language	English
Pages (from-to)	2715-2731
Number of pages	17
Journal	Thoracic Cancer
Volume	14
Issue number	26
DOIs	https://doi.org/10.1111/1759-7714.15022
State	Published - Sep 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

diagnosis
malignant pleural mesothelioma
prognosis
treatment

Access to Document

10.1111/1759-7714.15022

Cite this

@article{84f8e7da433642c2babf35a9d3c29f84,

title = "Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma",

abstract = "Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high-risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow-up.",

keywords = "diagnosis, malignant pleural mesothelioma, prognosis, treatment",

author = "Qian Wang and Chunwei Xu and Wenxian Wang and Yongchang Zhang and Ziming Li and Zhengbo Song and Jiandong Wang and Jinpu Yu and Jingjing Liu and Shirong Zhang and Xiuyu Cai and Wen Li and Ping Zhan and Hongbing Liu and Tangfeng Lv and Liyun Miao and Lingfeng Min and Jiancheng Li and Baogang Liu and Jingping Yuan and Zhansheng Jiang and Gen Lin and Xiaohui Chen and Xingxiang Pu and Chuangzhou Rao and Dongqing Lv and Zongyang Yu and Xiaoyan Li and Chuanhao Tang and Chengzhi Zhou and Junping Zhang and Hui Guo and Qian Chu and Rui Meng and Xuewen Liu and Jingxun Wu and Xiao Hu and Jin Zhou and Zhengfei Zhu and Xiaofeng Chen and Weiwei Pan and Fei Pang and Wenpan Zhang and Qijie Jian and Kai Wang and Liping Wang and Youcai Zhu and Guocai Yang and Xinqing Lin and Jing Cai and Huijing Feng and Lin Wang and Yingying Du and Wang Yao and Xuefei Shi and Xiaomin Niu and Dongmei Yuan and Yanwen Yao and Jianhui Huang and Xiaomin Wang and Yinbin Zhang and Pingli Sun and Hong Wang and Mingxiang Ye and Dong Wang and Zhaofeng Wang and Yue Hao and Zhen Wang and Bing Wan and Donglai Lv and Jianwei Yu and Jin Kang and Jiatao Zhang and Chao Zhang and Lixin Wu and Lin Shi and Leiguang Ye and Gaoming Wang and Yina Wang and Feng Gao and Jianfei Huang and Guifang Wang and Jianguo Wei and Long Huang and Bihui Li and Zhang Zhang and Zhongwu Li and Yueping Liu and Yuan Li and Zhefeng Liu and Nong Yang and Lin Wu and Qiming Wang and Wenbin Huang and Zhuan Hong and Guansong Wang and Fengli Qu and Meiyu Fang and Yong Fang and Xixu Zhu and Kaiqi Du and Jiansong Ji and Yi Shen and Jing Chen and Yiping Zhang and Shenglin Ma and Yuanzhi Lu and Yong Song and Anwen Liu and Wenzhao Zhong and Wenfeng Fang",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley \& Sons Australia, Ltd.",

year = "2023",

month = sep,

doi = "10.1111/1759-7714.15022",

language = "英语",

volume = "14",

pages = "2715--2731",

journal = "Thoracic Cancer",

issn = "1759-7706",

publisher = "John Wiley and Sons Inc",

number = "26",

}

Wang, Q, Xu, C, Wang, W, Zhang, Y, Li, Z, Song, Z, Wang, J, Yu, J, Liu, J, Zhang, S, Cai, X, Li, W, Zhan, P, Liu, H, Lv, T, Miao, L, Min, L, Li, J, Liu, B, Yuan, J, Jiang, Z, Lin, G, Chen, X, Pu, X, Rao, C, Lv, D, Yu, Z, Li, X, Tang, C, Zhou, C, Zhang, J, Guo, H, Chu, Q, Meng, R, Liu, X, Wu, J, Hu, X, Zhou, J, Zhu, Z, Chen, X, Pan, W, Pang, F, Zhang, W, Jian, Q, Wang, K, Wang, L, Zhu, Y, Yang, G, Lin, X, Cai, J, Feng, H, Wang, L, Du, Y, Yao, W, Shi, X, Niu, X, Yuan, D, Yao, Y, Huang, J, Wang, X, Zhang, Y, Sun, P, Wang, H, Ye, M, Wang, D, Wang, Z, Hao, Y, Wang, Z, Wan, B, Lv, D, Yu, J, Kang, J, Zhang, J, Zhang, C, Wu, L, Shi, L, Ye, L, Wang, G, Wang, Y, Gao, F, Huang, J, Wang, G, Wei, J, Huang, L, Li, B, Zhang, Z, Li, Z, Liu, Y, Li, Y, Liu, Z, Yang, N, Wu, L, Wang, Q, Huang, W, Hong, Z, Wang, G, Qu, F, Fang, M, Fang, Y, Zhu, X, Du, K, Ji, J, Shen, Y, Chen, J, Zhang, Y, Ma, S, Lu, Y, Song, Y, Liu, A, Zhong, W & Fang, W 2023, 'Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma', Thoracic Cancer, vol. 14, no. 26, pp. 2715-2731. https://doi.org/10.1111/1759-7714.15022

TY - JOUR

T1 - Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

AU - Wang, Qian

AU - Xu, Chunwei

AU - Wang, Wenxian

AU - Zhang, Yongchang

AU - Li, Ziming

AU - Song, Zhengbo

AU - Wang, Jiandong

AU - Yu, Jinpu

AU - Liu, Jingjing

AU - Zhang, Shirong

AU - Cai, Xiuyu

AU - Li, Wen

AU - Zhan, Ping

AU - Liu, Hongbing

AU - Lv, Tangfeng

AU - Miao, Liyun

AU - Min, Lingfeng

AU - Li, Jiancheng

AU - Liu, Baogang

AU - Yuan, Jingping

AU - Jiang, Zhansheng

AU - Lin, Gen

AU - Chen, Xiaohui

AU - Pu, Xingxiang

AU - Rao, Chuangzhou

AU - Lv, Dongqing

AU - Yu, Zongyang

AU - Li, Xiaoyan

AU - Tang, Chuanhao

AU - Zhou, Chengzhi

AU - Zhang, Junping

AU - Guo, Hui

AU - Chu, Qian

AU - Meng, Rui

AU - Liu, Xuewen

AU - Wu, Jingxun

AU - Hu, Xiao

AU - Zhou, Jin

AU - Zhu, Zhengfei

AU - Chen, Xiaofeng

AU - Pan, Weiwei

AU - Pang, Fei

AU - Zhang, Wenpan

AU - Jian, Qijie

AU - Wang, Kai

AU - Wang, Liping

AU - Zhu, Youcai

AU - Yang, Guocai

AU - Lin, Xinqing

AU - Cai, Jing

AU - Feng, Huijing

AU - Wang, Lin

AU - Du, Yingying

AU - Yao, Wang

AU - Shi, Xuefei

AU - Niu, Xiaomin

AU - Yuan, Dongmei

AU - Yao, Yanwen

AU - Huang, Jianhui

AU - Wang, Xiaomin

AU - Zhang, Yinbin

AU - Sun, Pingli

AU - Wang, Hong

AU - Ye, Mingxiang

AU - Wang, Dong

AU - Wang, Zhaofeng

AU - Hao, Yue

AU - Wang, Zhen

AU - Wan, Bing

AU - Lv, Donglai

AU - Yu, Jianwei

AU - Kang, Jin

AU - Zhang, Jiatao

AU - Zhang, Chao

AU - Wu, Lixin

AU - Shi, Lin

AU - Ye, Leiguang

AU - Wang, Gaoming

AU - Wang, Yina

AU - Gao, Feng

AU - Huang, Jianfei

AU - Wang, Guifang

AU - Wei, Jianguo

AU - Huang, Long

AU - Li, Bihui

AU - Zhang, Zhang

AU - Li, Zhongwu

AU - Liu, Yueping

AU - Li, Yuan

AU - Liu, Zhefeng

AU - Yang, Nong

AU - Wu, Lin

AU - Wang, Qiming

AU - Huang, Wenbin

AU - Hong, Zhuan

AU - Wang, Guansong

AU - Qu, Fengli

AU - Fang, Meiyu

AU - Fang, Yong

AU - Zhu, Xixu

AU - Du, Kaiqi

AU - Ji, Jiansong

AU - Shen, Yi

AU - Chen, Jing

AU - Zhang, Yiping

AU - Ma, Shenglin

AU - Lu, Yuanzhi

AU - Song, Yong

AU - Liu, Anwen

AU - Zhong, Wenzhao

AU - Fang, Wenfeng

PY - 2023/9

Y1 - 2023/9

N2 - Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high-risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow-up.

AB - Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high-risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow-up.

KW - diagnosis

KW - malignant pleural mesothelioma

KW - prognosis

KW - treatment

UR - https://www.scopus.com/pages/publications/85165286682

U2 - 10.1111/1759-7714.15022

DO - 10.1111/1759-7714.15022

M3 - 文章

C2 - 37461124

AN - SCOPUS:85165286682

SN - 1759-7706

VL - 14

SP - 2715

EP - 2731

JO - Thoracic Cancer

JF - Thoracic Cancer

IS - 26

ER -

Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this